Corporate GovernanceJul 9, 2026, 06:08 AM
Takeda Details 2026 Corporate Governance Structure & Policies
AI Summary
Takeda Pharmaceutical Company Limited has published its 2026 Corporate Governance Report, detailing its commitment to a global, values-based, R&D-driven biopharmaceutical company structure. The report outlines the company's compliance with the Corporate Governance Code, emphasizing strong internal controls, risk management, and transparent decision-making. Key aspects include a Board of Directors with a majority of Independent External Directors, robust shareholder engagement practices, and initiatives in sustainability, diversity, and capital efficiency.
Key Highlights
- Takeda's Board of Directors comprises 11 members, with 8 being Independent External Directors.
- The Board meeting is chaired by an Independent External Director to enhance objectivity.
- Nomination and Compensation Committees are voluntary and composed entirely of External Directors.
- The company conducts an annual evaluation of Board effectiveness using third-party organizations.
- Global workforce has 43% women in management positions as of March 31, 2026.
- Japan's female manager ratio is 22.5%, non-Japanese managers 4.1%, and mid-career managers 46.6%.
- Foreign shareholding ratio is over 30% as of the end of March 2026.
- The Master Trust Bank of Japan, Ltd. holds 16.84% of shares as the largest shareholder.
Price Impact
More from TAK